Why USANA Health Sciences Shares Shot Up
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of USANA Health Sciences gained as much as 19% after the company delivered an impressive fourth quarter earnings report.
So what:The multilevel marketer of health supplements said quarterly earnings per share improved to $1.41, better than estimates of $1.37, while sales moved up 10.5% to $186.3 million, also beating the experts' mark. CEO Dave Wentz credited the successful execution of recent company initiatives for the standout quarter. USANA's outlook for 2014 was also promising: the company sees revenue of $790 to $810 million and EPS of $5.80 to $5.95. Analysts had expected sales of just $750.5 million and a per-share profit of $5.63.
Now what: Beating estimates is always a strong sign for a company, but USANA's report comes at a particularly crucial time, just weeks after China accused rival Nu Skin Enterprises of operating as a pyramid scheme. That sent shares of Nu Skin and other industry stocks plummeting as they tend to trade in tandem and are often subject to similar accusations. However, USANA's report today makes it clear that the stock's prospects are solid and growing. As CFO Paul Jones said in a press release, "We expect that growth during 2014 will accelerate as the year progresses." It's hard to argue with an endorsement like that.
What else is poised to pop
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.
The article Why USANA Health Sciences Shares Shot Up originally appeared on Fool.com.
Jeremy Bowman has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.